Fragile X Syndrome – Epidemiology – Mature Markets
DRG Epidemiology’s coverage of fragile X syndrome (FXS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report the total prevalence of FXS for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
DRG Epidemiology’s FXS forecast will answer the following questions
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of FXS over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts the following FXS patient population:
- Total prevalent cases.
Note: Coverage may vary by country.
Table of contents
- Fragile X Syndrome - Epidemiology - Mature Markets
- Introduction
- Abstract
- Key Findings
- Key Updates
- Prevalence of Fragile X Syndrome per 100,000 People of All Ages in 2021 and 2041
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Fragile X Syndrome over the Next 20 Yearsttttttttt
- Epidemiology Data
- Methods
- Total Prevalent Cases
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Fragile X Syndrome
- Studies Excluded from the Analysis of Fragile X Syndrome
- Risk/Protective Factors
- Risk/Protective Factors for Fragile X Syndrome
- Bibliography
- Glossary
- Literature Review
- Introduction
Latashree Goswami, M.P.H., is an associate epidemiologist at Clarivate. She holds an M.P.H. from the Indian Institute of Public Health where she specialized in health economics, financing, and policy, and a B.D.S. from India’s ITS Dental College.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.